For instance, the tumor necrosis factor-alpha (TNF-α) inhibitor infliximab has been shown to have antidepressant effects in treatment-resistant depression, particularly in patients with elevated levels of C-reactive protein (CRP). Here, CRP is linked to depressive symptom measurement.